Sturge-Weber Syndrome

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will be exhibiting onsite at booth #631. In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled, “The Catalysts to Advance the Interventional Glaucoma Revolution: iDose® TR (travoprost intracameral implant) 75 mcg and iStent infinite®” on Friday, April 5, 2024, at 12:00-1:00 p.m. ET in Room 252AB at the Boston Convention & Exhibition Center. The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD. Go here for more information and to register. Key Glaucoma Presentations: Saturday, April 6, 2024 10:28-10:33 a.m., I. Paul Singh, MD Efficacy of Travoprost Intraocular Implant in Diverse Subpopulations of Patients with Open-Angle Glaucoma or Ocular Hypertension 10:33-10:38 a.m., Christy Benson, MD Early Outcomes After Third-Generation Trabecular Micro-Bypass with/without Goniotomy in Eyes with Failed Prior Glaucoma Intervention 10:33-10:38 a.m., Cristos Ifantides, MD, MBA Two-Year Comparison of 2 Trabecular MIGS Devices in Patients with Mild to Severe Open-Angle Glaucoma 10:38-10:43 a.m., Steven Sarkisian, MD Standalone Procedure of Administration of Travoprost Intraocular Implant is Safe and Effective in Phakic Eyes 10:43-10:48 a.m., Rom Kandavel, MD 12-Month Efficacy Results of Trabecular Micro-Bypass in Patients Stratified by Prior Laser or Incisional Glaucoma Surgery 10:51-10:56 a.m., John Berdahl, MD Travoprost Intraocular Implant in Eyes with Prior Selective or MicroPulse Laser Trabeculoplasty Sunday, April 7, 2024 8:50-8:55 a.m., Ali Salimi, MD A Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma 9:05-9:10 a.m., Mitchell Schultz, MD Preliminary Outcomes of 3 Microstents as Trabecular MIGS Device with or without Canaloplasty in Mild and Moderate Open-Angle Glaucoma Key Glaucoma Posters: Jason Bacharach, MD Travoprost Intraocular Implant: Analysis of Topical Prostaglandin Analog-associated Adverse Events Fritz Hengerer, MD 7-Year Outcomes after Second-Generation Trabecular Micro-Bypass in Eyes with or without Prior Glaucoma Surgery Brittany Long Comparison of Two Different MIGS Devices with Combined Canaloplasty in Moderate Glaucoma at the Time of Cataract Surgery Deborah Ristvedt, DO Third-Generation Trabecular Micro-Bypass in Eyes Failing Prior Surgical and/or Medical Glaucoma Therapy Valerie Trubnik, MD Usage of Three Trabecular Mico-Bypass Stents Combined with Phacoemulsification in Surgically Naïve Glaucoma Patients Zachary Vest, MD Early Outcomes After Third-Generation Trabecular Micro-Bypass Performed with Phacoemulsification in Patients with Open-Angle Glaucoma Edward Yung, MD Outcomes after Viscoelastic Delivery in Patients with Glaucoma Key Corneal Health Presentations: Friday, April 5, 2024 9:13-9:21 a.m., Michael Raizman, MD Cross-Linking – Now and What’s Coming Saturday, April 6, 2024 3:31-3:41 p.m., Brandon Ayres, MD Keratoconus – Surgical Innovations Sunday, April 7, 2024 10:00-10:05 a.m., Kenneth Beckman, MD Safety of a Scanning Laser-based Bioactivation System for Corneal Cross-Linking in Keratoconus Abstract information can be found at . The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services. About Glaukos Glaukos ( ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases. About iDose® TR (U.S.) iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration and indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for 24/7 release of medication. Indication for Use: iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). Dosage and Administration: For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. Contraindications: iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. Warnings and Precautions: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. Adverse Reactions: In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. About iStent infinite® Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit . Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety pro our products as might be suggested in the presentations at the ASCRS meeting. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2024. Our filings with the SEC are available in the Investor Section of our website at or at . In addition, information about the risks and benefits of our products is available on our website at . All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA. Glaukos will be exhibiting onsite at booth #1237. Key Glaucoma Presentations: Saturday, May 6, 2023 1:30 – 1:35 p.m., Gerd U. Auffarth, MD, Ph.D. Sustained 7-Year Glaucoma Control after Second-Generation Trabecular Micro-Bypass with or without Cataract Surgery 2:06 – 2:11 p.m., Ike K. Ahmed, MD Prospective Study of Standalone Multiple Trabecular Micro-Bypass Stents for Uncontrolled Glaucoma 2:16 – 2:21 p.m., John P. Berdahl, MD Outcomes of the Prospective Randomized Controlled Multicenter Phase III Trials of iDose® TR Versus Topical Timolol 2:21 – 2:26 p.m., Mitchell C. Shultz, MD Stratified Outcomes of 2 Different Trabecular MIGS Devices with or without Ab-Interno Canaloplasty in Mild and Moderate Open-Angle Glaucoma 2:52 – 2:57 p.m., Ticiana De Francesco, MD Long-Term Endothelial Safety with 2nd-Generation Trabecular Micro-Bypass in Patients with Open-Angle Glaucoma Key Glaucoma Posters: Tanner J. Ferguson, MD iStent inject® Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Open-Angle Glaucoma: Long-Term Results Mark J. Gallardo, MD Trabecular Micro-Bypass +/- Precision Blade Goniotomy to Potentiate Aqueous Outflow & Reduce Intraocular Pressure in Glaucoma Ae Ra Kee, MBBS, FRCOphth Combined Phacoemulsification and iStent inject versus Combined Phacoemulsification and Hydrus® Microstent in South East Asian Eyes Xiongfei Liu, MD Effectiveness and Safety of Combining Two MIGS Devices in Patients with Open-Angle Glaucoma Mitchell C. Shultz, MD Effectiveness and Safety of 2 Different Trabecular MIGS Devices in Patients with Mild-to-Moderate Glaucoma Key Corneal Health Presentations: Saturday, May 6, 2023 1:30 – 1:35 p.m., Miguel Rechichi, Ph.D., MD Eight Year Results of Accelerated Epi-off™ Corneal Cross-Linking in Patients with Progressive Keratoconus Sunday, May 7, 2023 1:40 – 1:45 p.m., Steven Greenstein, MD 10-Year Follow-up for Collagen Cross-Linking in Keratoconus and Ectasia: Comparison of Outcomes with Subsequent Topography-Altering Surgery 1:45 – 1:50 p.m., Julia Yu, BSc Dynamics of Corneal Swelling during Corneal Collagen Cross-Linking in Progressive Keratoconus Patients 1:51 – 1:56 p.m., Miltos Balidis, Ph.D., MD Customized Transepithelial Cross-Linking for Keratoconus: 2-Year Follow-up 2:11 – 2:16 p.m., Philip Dockery, MD Corneal Cross-Linking for Patients with Progressive Keratoconus and Thin Corneas 3:47 – 3:55 p.m., Kenneth A. Beckman, MD Update on Cross-Linking: Epi-on™ FDA Trial and Beyond Key Corneal Health Posters: Brendan G. Cronin, FRANZCO, MBBS Oxygen-Supplemented and Topography-Guided Epi-on Corneal Cross-Linking with Pulsed Irradiation for Progressive Keratoconus Key Corneal Health Course: Saturday, May 6, 2023 8:00 – 9:30 a.m., Miguel Rechichi, Ph.D., MD Keratoconus State of the Art: New Cutting-Edge Treatments for Corneal Ectasia (IC-105) Co-instructors: Ashraf Armia Balamoun, MD, Miltiadis Balidis, PhD, MD, William B. Trattler, MD Abstract information can be found at . The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS annual meeting is planned by its program committee. ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services. About Glaukos Glaukos ( ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases. About iStent inject W Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent inject W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma. Contraindications: The iStent inject W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent inject W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents. Adverse Events: Common postoperative adverse events reported in the iStent inject randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit . iDose TR and Epi-on are investigational therapies and not currently approved by the FDA. Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety pro our products as might be suggested in the presentations at the ASCRS meeting. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Quarterly Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission (SEC) on February 24, 2023. Our filings with the SEC are available in the Investor Section of our website at or at . In addition, information about the risks and benefits of our products is available on our website at . All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

DEDHAM, Mass.--( BUSINESS WIRE )-- Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m. ET) in San Francisco. Htoo will participate in the session titled “Delivering Glaucoma Solutions” and will provide updates on Qlaris Bio’s plans for 2023 and the company’s novel ATP-sensitive potassium (K ATP ) channel modulator platform currently in development to treat a range of glaucomas, including normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), and glaucoma related to rare diseases such as Sturge-Weber Syndrome. “It is an exciting time for Qlaris and the future of glaucoma therapy,” said Htoo. “Our company is developing a treatment focused on reducing episcleral venous pressure (EVP), which is not a primary target of existing glaucoma therapies, despite being a significant component of intraocular pressure (IOP). I am looking forward to sharing updates on Qlaris’ program and our anticipated milestones for the coming year.” The Glaucoma 360 New Horizons Forum is hosted by the Glaucoma Research Foundation and brings together clinical, industry, financial, and FDA leaders to discuss research innovation and advances in glaucoma treatment. Register for the event here . About Qlaris Bio, Inc. Qlaris Bio, Inc., was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and debilitating ophthalmic diseases. The company’s lead platform is based on the use of adenosine triphosphate (ATP)-sensitive potassium (K ATP ) channel modulators to affect the tone of vascular and vascular-like tissues for ophthalmic use. Qlaris Bio’s investors include Canaan and New Leaf Venture Partners, both of which were co-lead investors in the company’s $25 million Series A round in August 2019. Other investors include Correlation Ventures and Mayo Clinic. For more information, please visit qlaris.bio .